valu usd unless otherwis note
post-cal strong price
competit concern continu weigh
view continu like strong growth potenti
oper execut team defend grow base
busi expand new market competit price
concern continu remain concern given revenu still concentr
though see eas ultomiri defens potenti valid
especi europ
report result highlight strength complement
franchis growth across indic strong uptak soliri
gmg howev price concern ex-u biosimilar risk ex-u
overshadow beat rais morn report
result top-line product revenu beat vs st
rais soliris/ultomiri revenu guid increas
see first blush note franchis
product revenu beat driven strong ultomiri sale vs st
back favor switch trend soliri treat us
pnh patient switch ultomiri soliri continu growth gmg
patient treat offset rapid pnh switch
ultomiri encouragingli convers management suggest
franchis continu see high single-digit growth pnh/ahu
indic franchis guidanc increas investor focus
convers call detail cumul impact
soliri canada sinc septemb result price pressur
territori convers management suggest
pressur local canada specif price concern remain
linger risk head us elect cycl
model chang updat model financi result
guidanc notabl increas ultomiri sale estim
vs previou reflect increas complement revenu
guidanc fast switch rate soliri treat pnh patient strong
sale ultomiri also adjust metabol franchis revenu
strensiq kanuma reflect guidanc updat
model reflect oper margin improv
reduct expens project howev
model number clinic trial initi like increas
 spend compress margin continu invest
late-stag pipelin use dcf valuat methodolog vs prior npv
sotp reach pt maintain outperform rate
upcom catalyst epo hear regard soliri eu patent
sep ii readout competitor pnh dec iii initi
studi ultomiri nmosd
continu page
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
price target base discount cash
flow dcf methodolog differ program contribut
follow soliri sale pnh soliri sale
ahu strensiq sale
kanuma sale lal-d soliri sale mg
soliri sale nmo ultomiri
sale pnh ultomiri
sale ahu ultomiri sale neuro
sale wilson diseas
sale net cash
price target support outperform rate
upsid scenario assum
approv wilson diseas po
approv mg waiha po
consensu ultomiri switch biosimilar competit
soliri appear europ increas soliri sale
downsid scenario assum assum
discount soliri npv base earlier-than-
anticip biosimilar entri solri indic
despit pnh patient competit like soliri
mg approv see declin soliri pnh sale
larg off-set expans ahu mg focu
long-term revenu expens guidanc amid intens
development competit field complement
inhibitor anticip restructur could help remov
near-term overhang stock follow manag
could help protect pnh ahu
market competitor see dose
regimen promis highli conveni though riski
development strategi present pk
dose use remain unclear
whether recycl strategi use extend half
life hold high concentr note
therapeut antibodi commerci
high dose though conced dose would
like seen conveni mani competitor
ip extens like fend soliri biosimilar
see recent composit matter formul
method use patent extend ip us
hold launch biosimilar anticip
issuanc similar patent eu extend
protect eu countri view biosimilar soliri
near-term threat
soliri eu patent sep ii readout competitor
pnh dec iii initi studi
ultomiri nmosd iv initi proof concept
studi ultomiri al earli initi
studi waiha vi complet trial
enrol studi
risk factor neg influenc valuat
rate includ biosimilar competit soliri eu
patent valid eu price pressur ex-u market
posit develop progress competitor complement
iv initi proof concept studi ultomiri al earli initi
studi waiha vi complet trial enrol
studi
brand biosimilar competit catalyst continu overhang despit oper
key investor concern despit increas evid biosimilar still away base
current develop recent launch ultomiri pnh eu addit
note increas competit concern studi vs soliri pnh
pegasu studi readout dec could add benefit/differenti subset
pnh patient convers management note could add benefit
fraction soliris/ultomiri treat pnh patient extravascular hemolysi immunobiolog
high bar efficaci set agent
price pressur soliri sale ex-u market remain focu increas attent
canada pend final judici decis patent medicin price review board
pmprb canada issu decis state excess price soliri canada
vs countri last hear held new earn slide
detail specif cumul neg impact per move forward
soliri sale sep june follow convers management
team confid case howev highlight fine could
levi assum soliri sale canada excess revenu base excess
revenu earn canada period file management indic
issu canada-specif investor concern linger possibl ex-
us market might see similar price pressur addit concern around us market
light current administr propos intern price index determin
appropri reimburs pharmaceut product howev actual implement
index remain question aim keep narrow price brand global
product see intern price index concern medicar
busi small portion overal busi
like ultomiri eu price strategi discount soliri pnh higher
indic dont see soliri biosimilar launch materi risk ultomiri sale ex-u
market think unlik soliri biosimilar compress ultomiri price
major indic gmg pnh ahu given ultomiri market discount
soliri pnh eu line us price note ultomiri price repres
even higher price save ahu gmg agent util dose vs
higher dose requir soliri indic vs pnh
switch us pnh patient soliri ultomiri remain well ahead
goal could slow current blister rate market grow satur
announc switch us pnh patient soliri ultomiri
updat patient switch rate track close analysi see exhibit
indic switch complet use linear best-fit trend-line howev
note gap patient enrol onesourc program actual patient
switch narrow vs previou updat show differ recent
updat suggest enrol onesourc may slow switch patient
sourc new ultomiri patient constitut major revenu
seen conserv model averag convers rate
respect
trial initi resolut root-caus impur
clinic sampl recal push back clinic develop plan
syntimmun acquisit due impur found clinic sampl
management assur underli root caus address remain track
resum drug suppli mid-dec delay initi
clinic studi waiha gmg indic like prudent approach taken ensur
regulatori delay
price target base discount cash flow dcf methodolog
differ program contribut follow soliri sale pnh soliri sale
ahu strensiq sale kanuma sale lal-d
share soliri sale mg soliri sale nmo ultomiri
sale pnh ultomiri sale ahu ultomiri
sale neuro sale wilson diseas
sale net cash price target support outperform
risk rate price target
factor neg influenc valuat rate includ develop
set-back includ neg readout studi ahu posit develop
progress competitor complement program
alexion pharmaceut global fulli integr biopharmaceut compani
focus treatment rare diseas lead commerci product soliri eculizumab
human monoclon antibodi direct complement factor soliri approv
treatment paroxysm nocturn hemoglobinuria pnh atyp hemolyt urem
syndrom ahu gener myasthenia gravi three ultra-rar diseas caus
uncontrol complement activ alexion aim expand soliri neurolog
transplant disord conduct late-stag develop program neuromyel optica
nmo delay graft function dgf antibody-medi reject amr
alexion also market strensiq asfotas alfa enzym replac therapi ert indic
hypophosphatasia grant us approv octob eu approv
septemb approv japan juli addit
acquisit synageva alexion own kanuma sebelipas alfa ert treatment
lysosom acid lipas defici lal-d receiv eu us market approv
septemb decemb respect approv japan march
compani current develop next gener complement inhibitor
treatment pnh ahu potenti complement associ diseas
compani report capit market estim
chang model revenu expens expens expens incom incom expens incom incom non- non- exhibit incom statement
compani report capit market estim
incom statement mm fy soliri net ultomiri sale net complement net strensiq net kanuma net sale risk adjust net metabol net revenues- sale mg- sale waiha- net product contract research revenues- total other- gross sg impair intang amort purchas intang chang fair valu conting acquisition-rel costs- restructur total oper oper incom loss oper incom invest interest foreign currenc gain loss debt exchang expense- net incom incom tax tax net incom basic ep dilut exhibit dcf valuat
compani report capit market estim
valuat tax pv fcfe termin total ye net ye exhibit price target breakdown
compani report capit market estim
exhibit soliris-ultomiri switch us pnh patient calcul
compani report capit market estim
exhibit gmg patient soliri calcul
compani report capit market estim
